Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenzilumab and Axicabtagene Ciloleucel in Large B-cell Lymphoma
NCT04314843Phase 1Terminated
- Sponsor
- Kite Pharma
- Start
- May 2020
- Primary completion
- Mar 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of lenzilumab in diffuse large B-cell lymphoma (DLBCL), sponsored by Kite Pharma. Primary endpoints: Dose Limiting Toxicities at 28 days and Incidence of Neurologic Events at 28 days. Started May 2020; status: terminated.
02
Drugs
lenzilumab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT04314843.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04314843.